T1	Participants 49 54	STEMI
T2	Participants 177 232	Austrian multi-centre randomized ReoPro-BRIDGING Study.
T3	Participants 254 297	ReoPro-BRIDGING Austrian multi-centre study
T4	Participants 499 724	Fifty-five patients with STEMI were randomized either to start abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) during the organization phase for pPCI (Group 1, n=28) or immediately before pPCI (Group 2, n=27).
